Vor Biopharma Inc (NASDAQ:VOR) saw its stock decline 3.4% in premarket trading Thursday after the company filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its common stock by existing stockholders.
The shares would be issued through the exercise of outstanding warrants, including 16 million shares allocated to a subsidiary of RemeGen Co. Ltd. and roughly 35 million shares tied to investors from a June 2025 private placement.
The warrant issued to RemeGen was part of the consideration for a licensing agreement granting Vor Biopharma exclusive rights to develop and commercialize telitacicept outside Greater China. The remaining warrants were distributed to participants of the private placement that closed on June 27, 2025.
According to the prospectus, Vor Biopharma will not receive proceeds from the selling stockholders’ share sales, though the company would collect funds from any warrants exercised for cash. The selling stockholders may offer these shares through public markets or privately negotiated transactions at prevailing prices.
This filing follows closely on the heels of Vor Biopharma’s 1-for-20 reverse stock split of its common stock on September 18, 2025. The company’s shares had most recently closed at $31.28 per share on September 23, 2025.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.